Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-203 mimic is a synthetic double-stranded RNA molecule designed to emulate the biological activity of the endogenous microRNA miR-203, which functions as a tumor suppressor in various malignancies. In cancers such as renal cell carcinoma (RCC), miR-203 expression is frequently downregulated, contributing to tumor progression. The mimic works by restoring miR-203 levels, which subsequently targets and inhibits the expression of oncogenic factors, including the long non-coding RNA HOTAIR. This interaction leads to the suppression of epithelial-to-mesenchymal transition (EMT) and the reduction of cancer stemness markers. Preclinical research has demonstrated that miR-203 mimics can inhibit cell proliferation, migration, and invasion while inducing apoptosis in vitro, and significantly suppressing tumor growth in vivo mouse models.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on miR-203 mimic.